

Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 2, 2025

Genethon DNA and Cell Bank

RRID:SCR_004639

Type: Tool

Proper Citation

Genethon DNA and Cell Bank (RRID:SCR_004639)

Resource Information

URL: <http://www.genethon.fr/en/rd-2/dna-and-cell-bank/>

Proper Citation: Genethon DNA and Cell Bank (RRID:SCR_004639)

Description: Since its creation in 1990, the mission of the Genethon's DNA and Cell Bank is to promote advances in genetic research by providing the scientific community with a high quality cell and human tissue products resource. Europe's leading bank for genetic diseases, it serves the whole of the medical and scientific community. Each year, Genethon's DNA and Cell Bank: * Produces approximately 2,000 lymphoblastoid cell lines * Performs approximately 3,000 DNA extractions * Prepares primary myoblast and fibroblast cultures from approximately 100 biopsies Genethon has developed a computer database for ensuring sample management and traceability, which has been submitted to and approved by the CNIL. The Genethon DNA and Cell Bank has been AFNOR certified, according to French biological research center standard NF S 96-900. The activities of the DNA and Cell Bank are as follows: * Collecting blood or DNA from patients affected with genetic diseases and their families with the minimum identification data necessary for the monitoring and follow-up of samples. * Processing the samples in order to make them available to the scientific community and perpetuating DNA preservation (serum isolation and DNA extraction), isolating lymphocytes and establishing lymphoblastoid B lines and primary cultures (mainly myoblasts and fibroblasts). * Storing samples for future research and preserving the genetic heritage by ensuring the long-term physical security of the preserved samples. * Distributing samples as necessary for ongoing research while complying with the principles and laws of bioethics and using the best available technologies at minimum cost. All these activities are carried out following Standard Operating Procedures (SOP) validated by the Quality Assurance department at Genethon. The Bank is open to researchers in France or abroad wishing to store samples or use the services provided (extraction, establishment of cell lines etc.). Each sample received at Genethon is coded in order to guarantee confidentiality, in accordance with the rules established by the CNIL (French Data Protection Authority). All requests for collaboration with the DNA and Cell Bank

should be made in writing to Dr Safaa SAKER-DELYE.

Abbreviations: Genethon DNA and Cell Bank

Synonyms: Genethon DNA Cell Bank

Resource Type: cell repository, material resource, biomaterial supply resource

Keywords: cell, tissue, dna, lymphoblastoid cell line, myoblast, fibroblast, cell line, blood, serum, culture, frozen, dms0, genetic disease, family member, cancer, cardiomyopathy, dermatology, endocrinology, gastroenterology, hematology, chromosomal disease, nephrology, neurology, neuromuscular disease, ophtalmology, ear, nose, throat, psychiatry, rhumatology, rare syndrome

Related Condition: Genetic disease, Family member

Funding:

Availability: Collaborators: All requests for collaboration with the DNA and Cell Bank should be made in writing to Dr Safaa SAKER-DELYE.

Resource Name: Genethon DNA and Cell Bank

Resource ID: SCR_004639

Alternate IDs: nlx_63525

Old URLs: <http://www.genethon.fr/index.php?id=188&L=1>

Record Creation Time: 20220129T080225+0000

Record Last Update: 20250402T060355+0000

Ratings and Alerts

No rating or validation information has been found for Genethon DNA and Cell Bank.

No alerts have been found for Genethon DNA and Cell Bank.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](https://www.fdi-lab.com/sci-crunch).

Jauze L, et al. (2024) Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver. *JCI insight*, 9(11).

Lemoine J, et al. (2024) Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system. *Scientific reports*, 14(1), 21238.

Sobrinho S, et al. (2023) Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy. *Cell reports. Medicine*, 4(2), 100919.

Chen M, et al. (2023) Phenotype, genotype, and management of congenital fibrosis of extraocular muscles type 1 in 16 Chinese families. *Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie*, 261(3), 879.

Vu Hong A, et al. (2023) Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne muscular dystrophy. *Life science alliance*, 6(1).

Romano G, et al. (2022) Rescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA. *American journal of human genetics*, 109(8), 1534.

Corre G, et al. (2022) Lentiviral standards to determine the sensitivity of assays that quantify lentiviral vector copy numbers and genomic insertion sites in cells. *Gene therapy*, 29(9), 536.

Shi X, et al. (2021) Efficacy of AAV8-hUGT1A1 with Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNS patients. *Molecular therapy. Methods & clinical development*, 20, 287.

Bossaert M, et al. (2021) Transcription-associated topoisomerase 2 α (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands. *eLife*, 10.

Navarro S, et al. (2021) Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment. *Molecular therapy. Methods & clinical development*, 22, 350.

Costa-Verdera H, et al. (2021) Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates. *Nature communications*, 12(1), 6393.

Rai R, et al. (2020) Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome. *Nature communications*, 11(1), 4034.

Esselin F, et al. (2020) Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort. *Frontiers in neuroscience*, 14, 316.

Rivers E, et al. (2020) Wiskott Aldrich syndrome protein regulates non-selective autophagy and mitochondrial homeostasis in human myeloid cells. *eLife*, 9.

Charrier S, et al. (2019) Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID. *Molecular therapy. Methods & clinical development*, 15, 232.

Dong Z, et al. (2019) Genome Sequencing Explores Complexity of Chromosomal Abnormalities in Recurrent Miscarriage. *American journal of human genetics*, 105(6), 1102.

Lo Scudato M, et al. (2019) Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice. *Molecular therapy : the journal of the American Society of Gene Therapy*, 27(8), 1372.

Lattanzi A, et al. (2017) Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System. *Molecular therapy. Nucleic acids*, 7, 11.

Dannemann M, et al. (2016) Introgression of Neandertal- and Denisovan-like Haplotypes Contributes to Adaptive Variation in Human Toll-like Receptors. *American journal of human genetics*, 98(1), 22.

Ripoll C, et al. (2012) Molecular signatures of cardiac defects in Down syndrome lymphoblastoid cell lines suggest altered ciliome and Hedgehog pathways. *PloS one*, 7(8), e41616.